

Supporting Information

Fucose-Galactose Polymers Inhibit Cholera Toxin Binding to Fucosylated Structures and Galactose-Dependent Intoxication of Human Enteroids

Jakob Cervin^{1†}, Andrew Boucher^{1†}, Gyusaang Youn^{2‡}, Per Björklund^{3§}, Ville Wallenius^{3§}, Lynda Mottram^{1†}, Nicole S. Sampson^{2‡} and Ulf Yrlid^{1†}

[†] Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, 405 30 Gothenburg, Sweden

[‡] Department of Chemistry, Stony Brook University, Stony Brook, New York, 11794-3400, United States

[§] Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital/Östra, 416 85 Gothenburg, Sweden

Email: ulf.yrlid@gu.se

Content

Materials.....	4
General Methods.....	4
Monomer preparation.....	4
Synthesis of 2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside, 2-bromoethyl (2a')	4
Synthesis of 2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside, 2-Azidoethyl (3a')	4
Synthesis of 2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl bicyclo[2.2.1]hept-5-ene-exo-2-carboxamide (1a')	5
Synthesis of 1,2,3,4,6-penta-O-acetyl- β -D-galactopyranoside	5
Synthesis of 2,3,4,6-tetra-O-acetyl- β -D-galactopyranoside, 2-bromoethyl (2b')	5
Synthesis of 2,3,4,6-tetra-O-acetyl- β -D-galactopyranoside, 2-azidoethyl (3b')	6
Synthesis of 2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl bicyclo[2.2.1]hept-5-ene-exo-2-carboxamide (1b')	6
Synthesis of 2'-bromoethyl- α -L-fucopyranoside	6
Synthesis of 2,3,4-Tri-O-acetyl-2'-bromoethyl- α -L-fucopyranoside (2c')	7
Synthesis of 2,3,4-Tri-O-acetyl-2'-azidoethyl- α -L-fucopyranoside (3c)	7
Synthesis of 2,3,4-Tri-O-acetyl- α -L-fucopyranosyl bicyclo[2.2.1]hept-5-ene-exo-2-carboxamide (1c')	7
Figure S1. GPC traces of polymers displaying 100 sugar units.....	9
Figure S2. GPC traces of polymers with varying degrees of polymerization.....	10
Figure S3. Gating strategy for murine MLN cells.	11
Figure S4. Gating strategy for murine small intestinal cells.....	12
Figure S5. Flow cytometry evaluation of glycol-polymers to block CTB binding to murine lymphocytes.	13
Figure S6. Gating strategy for human small intestinal cells.	14
Figure S7. Gating strategy for human enteroid cells.....	15
¹ H-NMR spectrum of monomer 1a'	16
¹ H-NMR spectrum of monomer 1b'	17
¹ H-NMR spectrum of monomer 1c'	18
¹ H-NMR spectrum of pGlc ₁₀₀	19
¹ H-NMR spectrum of pGal ₁₀₀	20
¹ H-NMR spectrum of pFuc ₁₀₀	21
¹ H-NMR spectrum of pGal ₅₀ Fuc ₅₀	22
Stacked ¹ H-NMR spectra of pGal ₅ Fuc ₅ (green), pGal ₁₅ Fuc ₁₅ (red) and pGal ₅₀ Fuc ₅₀ (blue) in CDCl ₃	23
¹ H-NMR spectrum of Glc ₁₀₀	24
¹ H-NMR spectrum of Gal ₁₀₀	25
¹ H-NMR spectrum of Fuc ₁₀₀	26
¹ H-NMR spectrum of Gal ₅₀ Fuc ₅₀	27

Stacked ^1H -NMR spectra of Gal₅Fuc₅ (green), Gal₁₅Fuc₁₅ (red) and Gal₅₀Fuc₅₀ (blue) in D₂O..... 28

Materials


Materials were purchased from Sigma Aldrich, Fisher Scientific, VWR, Santa Cruz Biotechnology, Neta Scientific and used as received unless otherwise specified. Solvents (tetrahydrofuran, methanol, diethyl ether, dimethylformamide, dichloromethane) were purified by Pushstill (Glass Contour System).

General Methods

Analytical thin-layer chromatography was performed on an aluminum backed sheets coated with silica gel 60 F254 as an indicator. For non-UV active compounds, the TLC plates were stained with 10% phosphomolybdic acid in ethanol or Hanessian's stain. LCMS(ESI) were recorded using an Agilent LC-MSD consisting of an 1100 HPLC and a G1956A mass spectrometer. HRMS(ESI) were performed with Agilent LC-UV-TOF consisting of a 1260 UPLC, a UV-Vis diode-array detector (DAD) and a TOF mass analyzer. Flash column chromatography was performed using a flash chromatography system with normal phase silica columns (silica gel 60, 230–400 mesh). HPLC was performed using a Shimadzu HPLC system with a system controller (CBM-20A), a degasser (DGU-20A 3R), binary solvent delivery unit (LC-20AT), a column oven (CTO-20AC), an evaporative light scattering detector (ELSD-LT II). Methanol or acetonitrile and 20 mM ammonium acetate were used as eluents with a reverse-phase column (Phenomenex Jupiter 5u C4 300A). Air and/or moisture sensitive reactions were carried out either using a glovebox under nitrogen atmosphere or a standard Schlenk vacuum technique under argon. *d*-Chloroform and *d*₂-water were purchased from Cambridge Isotope Laboratories. All NMR spectra were collected in *d*-chloroform unless otherwise specified. NMR spectra were recorded on a Bruker Ascend 700 spectrometer (¹H-700 MHz, ¹³C-176MHz) and a Bruker 500 Advance spectrometer (¹H-500 MHz, ¹³C-125 MHz). Chemical shifts were recorded in ppm relative to the residual solvent peaks; CDCl₃ (¹H δ7.28; ¹³C δ77.16), D₂O (¹H δ4.79). Purities of each final monomer were assessed using two or more of the following techniques: TLC, ¹H-NMR spectroscopy, or HPLC, and the method used for reporting is indicated.


Monomer preparation

Synthesis of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside, 2-bromoethyl (2a')



To a mixture of 1,2,3,4,6-penta-O-acetyl-β-D-glucopyranoside (5.12 mmol, 2.00 g) and 2-bromoethanol (55 mmol, 3.2 mL) in CH₂Cl₂ (20 mL), boron trifluoride dietherate (30 mmol, 3.6 mL) was added dropwise at 0 °C and the temperature was raised to 20 °C upon completion of addition. After 3 h, the reaction was quenched with saturated sodium bicarbonate solution, extracted with 20 mL of EtOAc and concentrated followed by column chromatography (EtOAc:Hexane) to afford **2a'** as a white solid (1.68 mmol, 762 mg, 33%). The NMR spectra matched the literature.¹ ¹H NMR (500 MHz, CDCl₃) δ 5.24 (t, *J* = 9.5 Hz, 1H), 5.11 (t, *J* = 9.7 Hz, 1H), 5.04 (q, *J* = 5.9 Hz, 1H), 4.60 (d, *J* = 8.0 Hz, 1H), 4.28 (q, *J* = 5.7 Hz, 1H), 4.16 (m, *J* = 3.4 Hz, 2H), 3.84 (m, *J* = 3.6 Hz, 1H), 3.73 (m, *J* = 2.5 Hz, 1H), 3.49 (m, *J* = 2.2 Hz, 2H), 2.12 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 170.67 170.28 169.44 169.42 101.03 72.59 71.93 71.01 69.80 68.30 61.83 29.88 20.76 20.63 20.61. ESI-MS (*m/z*) calcd for C₁₆H₂₇BrNO₁₀; [M + NH₄]⁺: 472.08, found: 472.1


Synthesis of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside, 2-Azidoethyl (3a')



Hexose **2a'** (1.68mmol, 762 mg) and sodium azide (5.94mmol, 386 mg) were dissolved in DMF (35 mL). The reaction vessel was maintained at 70 °C for 72 h. The reaction mixture was diluted with acetone (50 mL) and filtered through celite then concentrated. The concentrated solution was diluted with toluene then washed 3 times with water (30 mL) and once with brine. The organic


layer was concentrated to provide a brown solid. (1.10 mmol, 455 mg, 66%). The spectra matched the literature.² ¹H NMR (700 MHz, CDCl₃) δ 5.24 (t, *J* = 9.5 Hz, 1H), 5.13 (t, *J* = 9.7 Hz, 1H), 5.05 (q, *J* = 5.9 Hz, 1H), 4.62 (d, *J* = 8.0 Hz, 1H), 4.28 (q, *J* = 5.7 Hz, 1H), 4.19 (q, *J* = 4.9 Hz, 1H), 4.06 (m, *J* = 2.7 Hz, 1H), 3.73 (m, *J* = 2.8 Hz, 2H), 3.52 (m, *J* = 5.5 Hz, 1H), 3.31 (m, *J* = 3.6 Hz, 1H), 2.12 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 170.69 170.31 169.43 169.41 100.67 72.78 71.94 71.05 68.58 68.29 61.82 50.52 20.76 20.70 20.61. ESI-MS (*m/z*) calcd for C₁₆H₂₇N₄O₁₀; [M + NH₄]⁺: 435.17, found: 435.2

Synthesis of 2,3,4,6-Tetra-*O*-acetyl-β-*D*-glucopyranosyl bicyclo[2.2.1]hept-5-ene-*exo*-2-carboxamide (**1a'**)




Hexose **3a'** (0.93 mmol, 389 mg), *exo*-5-norbornene-2-carboxylic acid (1.21 mmol, 170 mg) and EDC-HCl (1.21 mmol, 232 mg) were dissolved in anhydrous THF (20 mL). DIPEA (1.21 mmol, 0.21 mL) was added dropwise and stirred for 10 min with ice-bath cooling. Tributylphosphine (1.21 mmol, 0.30 mL) was added dropwise and the mixture was warmed to ambient temperature and allowed to react for 18 h at room temperature. The reaction mixture was diluted with DCM and subsequently washed 3 times with 1M HCl, once with saturated aq. NaHCO₃, and once with brine. After drying over MgSO₄ and filtering through Celite, the product was isolated by column chromatography (DCM:Acetone) as a white solid **1a'** (158.5 mg, 33%). The spectra matched the literature.² Purity by HPLC: 98.9%. ¹H NMR (700 MHz, CDCl₃) δ 6.15 (m, *J* = 6.6 Hz, 2H), 5.95 (s, 1H), 5.23 (t, *J* = 9.6 Hz, 1H), 5.11 (m, *J* = 4.5 Hz, 1H), 5.02 (t, *J* = 8.8 Hz, 1H), 4.54 (q, *J* = 3.3 Hz, 1H), 4.29 (m, *J* = 4.4 Hz, 1H), 4.16 (m, *J* = 3.5 Hz, 1H), 3.87 (m, *J* = 3.9 Hz, 1H), 3.74 (m, *J* = 2.9 Hz, 2H), 3.49 (m, *J* = 4.5 Hz, 2H), 2.94 (s, 2H), 2.11 (d, *J* = 2.2 Hz, 3H), 2.08 (d, *J* = 11.5 Hz, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.02 (q, *J* = 4.4 Hz, 1H), 1.93 (m, *J* = 3.7 Hz, 1H), 1.73 (t, *J* = 6.8 Hz, 1H), 1.37 (t, *J* = 9.3 Hz, 1H), 1.33 (m, *J* = 3.2 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 175.70 170.61 170.21 169.46 169.44 138.34 136.00 100.94 72.65 71.95 71.34 69.40 68.25 61.80 47.25 46.35 44.65 41.58 39.25 30.46 20.76 20.74 20.61. ESI-MS (*m/z*) calcd for C₂₄H₃₄NO₁₁; [M + H]⁺: 512.21, found: 512.2

Synthesis of 1,2,3,4,6-penta-*O*-acetyl-β-*D*-galactopyranoside



1,2,3,4,6-penta-*O*-acetyl-β-*D*-galactopyranoside was prepared by following the literature.³ D-galactose (1.00 g, 5.62 mmol), acetic anhydride (3.14 mL, 6 eq.) and sodium acetate (0.92g, 2 eq.) were irradiated under commercial microwave oven until all the solid dissolved in a solution. The solution was directly subject to precipitated in ice-water and the residue was collected by filtration. Multiple recrystallization was performed in ethanol to yield white crystal. (1.21 g, 55 %). ¹H NMR (700 MHz, CDCl₃) δ 5.72 (d, *J* = 8.3 Hz, 1H), 5.44 (d, *J* = 3.4 Hz, 1H), 5.35 (dd, *J* = 8.4, 10.4 Hz, 1H), 5.09 (dd, *J* = 3.4, 10.4 Hz, 1H), 4.16 (m, *J* = 6.4 Hz, 2H), 4.07 (t, *J* = 6.6 Hz, 1H), 2.18 (s, 3H), 2.14 (s, 3H), 2.06 (s, 6H), 2.01 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 170.36 170.13 169.98 169.39 168.99 92.15 71.69 70.83 67.80 66.78 61.02 31.26 20.83 20.66 20.64 20.55.


Synthesis of 2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranoside, 2-bromoethyl (**2b'**)



Hexose **2b'** was prepared by following the same procedure as for the preparation of **2a'**. Yield: 46 %. The NMR spectra of the product matched the literature¹. ¹H NMR (500 MHz, CDCl₃) δ 5.42 (d, *J* = 2.9 Hz, 1H), 5.26 (q, *J* = 6.1 Hz, 1H), 5.05 (q, *J* = 4.6 Hz, 1H), 4.56 (d, *J* = 8.0 Hz, 1H), 4.20 (m, *J* = 3.5 Hz, 2H), 3.94 (t, *J* = 6.6 Hz, 1H), 3.84 (m, *J* = 5.0 Hz, 1H), 3.49 (q, *J* = 4.6 Hz, 2H), 2.18


(s, 3H), 2.11 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.40 170.22 170.15 169.55 101.56 70.83 70.75 69.77 68.55 66.96 61.26 29.94 20.88 20.69 20.67 20.60. ESI-MS (m/z) calcd for $\text{C}_{16}\text{H}_{27}\text{BrNO}_{10}$; $[\text{M} + \text{NH}_4]^+$: 472.08, found: 472.1

Synthesis of 2,3,4,6-tetra-O-acetyl- β -D-galactopyranoside, 2-azidoethyl (3b')




Hexose **3b'** was prepared by following the same procedure as for the preparation of **3a'** and spectra matched the literature². Yield 87%. ^1H NMR (700 MHz, CDCl_3) δ 5.43 (d, $J = 3.3$ Hz, 1H), 5.27 (q, $J = 6.1$ Hz, 1H), 5.05 (q, $J = 4.6$ Hz, 1H), 4.59 (d, $J = 8.0$ Hz, 1H), 4.18 (m, $J = 8.4$ Hz, 2H), 4.07 (m, $J = 3.8$ Hz, 1H), 3.95 (t, $J = 6.7$ Hz, 1H), 3.72 (m, $J = 3.8$ Hz, 1H), 3.54 (m, $J = 4.2$ Hz, 1H), 3.33 (m, $J = 4.3$ Hz, 1H), 2.18 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H). ^{13}C NMR (176 MHz, CDCl_3) δ 170.40 170.24 170.17 169.49 101.17 70.92 70.84 68.54 68.40 67.02 61.27 50.59 20.79 20.70 20.68 20.59. ESI-MS (m/z) calcd for $\text{C}_{16}\text{H}_{27}\text{N}_4\text{O}_{10}$; $[\text{M} + \text{NH}_4]^+$: 435.17, found: 435.2

Synthesis of 2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl bicyclo[2.2.1]hept-5-ene-exo-2-carboxamide (1b')




Peracetylated glycomonomer **1b'** was prepared by following same the procedure as for the preparation of **1a'** to yield a white solid with spectra matching the literature². Yield: 58 %. Purity by HPLC: 97.5%. ^1H NMR (700 MHz, CDCl_3) δ 6.15 (m, $J = 2.9$ Hz, 1H), 6.11 (m, $J = 3.1$ Hz, 1H), 5.91 (d, $J = 3.3$ Hz, 1H), 5.40 (d, $J = 3.2$ Hz, 1H), 5.20 (m, $J = 3.4$ Hz, 1H), 5.02 (m, $J = 2.2$ Hz, 1H), 4.48 (q, $J = 3.7$ Hz, 1H), 4.15 (m, $J = 3.0$ Hz, 2H), 3.92 (t, $J = 6.6$ Hz, 1H), 3.89 (m, $J = 3.4$ Hz, 1H), 3.70 (m, $J = 3.4$ Hz, 1H), 3.51 (m, $J = 3.4$ Hz, 1H), 3.45 (q, $J = 3.1$ Hz, 1H), 2.92 (s, 2H), 2.16 (s, 3H), 2.06 (q, $J = 6.8$ Hz, 6H), 1.99 (s, 4H), 1.91 (m, $J = 3.8$ Hz, 1H), 1.71 (t, $J = 6.5$ Hz, 1H), 1.33 (m, $J = 4.2$ Hz, 2H). ^{13}C NMR (176 MHz, CDCl_3) δ 175.67 170.40 170.18 170.11 169.63 138.40 136.01 101.42 70.84 70.79 69.29 68.94 66.97 61.31 47.27 46.37 44.71 41.58 39.24 30.49 20.87 20.69 20.59. ESI-MS (m/z) calcd for $\text{C}_{24}\text{H}_{34}\text{NO}_{11}$; $[\text{M} + \text{H}]^+$: 512.21, found: 512.2

Synthesis of 2'-bromoethyl- α -L-fucopyranoside




To a flask containing L-fucose (4.00 g, 24.41mmol) and DOWEX 50W-X8 (2.86 g) was added 2-Bromoethanol (25 mL). The reaction temperature was maintained at 85 °C for 2 h, followed by filtration through a Celite pad. The resulting filtrate was concentrated under *vacuo*. An α -anomer was exclusively obtained as a white crystal **c'** by recrystallization from ethanol (5.07 g, 51%). NMR spectra matched the literature⁴. ^1H NMR (700 MHz, D_2O) δ 4.84 (d, $J = 4.0$ Hz, 1H), 4.10 (q, $J = 6.6$ Hz, 1H), 3.90 (m, $J = 4.6$ Hz, 1H), 3.80 (m, $J = 4.6$ Hz, 1H), 3.71 (d, $J = 3.3$ Hz, 1H), 3.69 (q, $J = 4.8$ Hz, 1H), 3.53 (q, $J = 3.9$ Hz, 2H), 1.12 (d, $J = 6.6$ Hz, 3H). ^{13}C NMR (176 MHz, D_2O) δ 98.47 71.75 69.48 68.30 67.93 66.98 31.21 15.19. ESI-MS (m/z) calcd for $\text{C}_8\text{H}_{19}\text{NO}_5$; $[\text{M} + \text{NH}_4]^+$: 288.04, found: 288.0

Synthesis of 2,3,4-Tri-O-acetyl-2'-bromoethyl- α -L-fucopyranoside (**2c'**)




2'-bromoethyl- α -L-fucose (255.74 mg, 0.968 mmol) was added to a 1:1 v/v mixture of pyridine and acetic anhydride (5 mL). After 18 h, the organic was subsequently washed 3 times with water, 3 times with aqueous 1M HCl, 3 times with saturated sodium bicarbonate and once with brine, followed by drying over magnesium sulfate and concentration *in vacuo*. Flash chromatography (EtOAc:Hex) was performed to obtain a white solid **2c'** (275.9 mg, 72 %) and the spectrum matched the literature.⁵ ¹H NMR (500 MHz, CDCl₃) δ 5.40 (q, *J* = 4.7 Hz, 1H), 5.34 (t, *J* = 1.6 Hz, 1H), 5.14 (m, *J* = 4.9 Hz, 2H), 4.28 (q, *J* = 6.5 Hz, 1H), 4.01 (m, *J* = 5.8 Hz, 1H), 3.83 (m, *J* = 5.8 Hz, 1H), 3.52 (t, *J* = 5.8 Hz, 2H), 2.19 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H), 1.17 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) 170.61 170.06 96.39 71.08 68.42 68.12 67.92 64.86 30.21 20.89 20.73 20.68 15.88. ESI-MS (*m/z*) calcd for C₁₄H₂₅BrNO₈; [M + NH₄]⁺: 414.07, found: 414.1

Synthesis of 2,3,4-Tri-O-acetyl-2'-azidoethyl- α -L-fucopyranoside (**3c**)



A solution of **2c'** (3.56 mmol, 1414 mg) and sodium azide (13.4 mmol, 870 mg) in DMF (20 mL) was heated to 80 °C for 18 h. The reaction mixture was diluted with toluene followed by filtered through Celite. The filtrate was subsequently washed 3 times with water and once with brine. The organic layer was dried over anhydrous magnesium sulfate followed by concentration *in vacuo*. The crude product was purified via flash chromatography (EtOAc:Hex) to obtain an orange solid **3c'** (913.7 mg, 71 %). The spectrum matched the literature.⁶ ¹H NMR (700 MHz, CDCl₃) δ 5.40 (q, *J* = 4.7 Hz, 1H), 5.35 (d, *J* = 2.9 Hz, 1H), 5.16 (m, *J* = 5.3 Hz, 2H), 4.21 (q, *J* = 6.5 Hz, 1H), 3.89 (m, *J* = 3.4 Hz, 1H), 3.64 (m, *J* = 3.5 Hz, 1H), 3.49 (m, *J* = 3.4 Hz, 1H), 3.40 (m, *J* = 3.2 Hz, 1H), 2.20 (s, 3H), 2.11 (s, 3H), 2.01 (s, 3H), 1.18 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 170.69 170.61 170.05 96.48 71.06 67.96 67.90 67.21 64.71 50.47 20.84 20.73 20.69 15.92. ESI-MS (*m/z*) calcd for C₁₄H₂₅N₄O₈; [M + NH₄]⁺: 377.17, found: 377.2

Synthesis of 2,3,4-Tri-O-acetyl- α -L-fucopyranosyl bicyclo[2.2.1]hept-5-ene-*exo*-2-carboxamide (**1c'**)



Peracetylated glycomonomer **1c'** was prepared by following the same procedure as for the preparation of **1a'** to yield a white solid (138.4mg, 36 %) and the spectrum matched the literature.² Purity by HPLC: 99.5%. ¹H NMR (700 MHz, CDCl₃) δ 6.18 (t, *J* = 2.6 Hz, 1H), 6.13 (m, *J* = 3.5 Hz, 1H), 5.90 (s, 1H), 5.39 (m, *J* = 3.8 Hz, 1H), 5.32 (t, *J* = 3.4 Hz, 1H), 5.18 (m, *J* = 2.7 Hz, 1H), 5.08 (t, *J* = 3.6 Hz, 1H), 4.16 (t, *J* = 7.0 Hz, 1H), 3.79 (m, *J* = 5.0 Hz, 1H), 3.53 (m, 3H), 2.95 (d, *J* = 9.0 Hz, 2H), 2.20 (s, 3H), 2.09 (d, *J* = 10.0 Hz, 3H), 2.02 (m, 4H), 1.94 (m, *J* = 3.7 Hz, 1H), 1.73 (d, *J* = 8.3 Hz, 1H), 1.38 (m, *J* = 5.2 Hz, 2H), 1.17 (q, *J* = 3.3 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 175.57 170.63 170.21 138.38 135.93 96.50 71.02 68.16 67.92 67.68 64.68 47.24 46.35 44.81 41.58 39.18 30.96 30.53 20.82 20.75 20.68 15.90. ESI-MS (*m/z*) calcd for C₂₂H₃₂NO₉; [M + H]⁺: 454.20, found: 454.2

NMR characterization of glycopolymers synthesized.

Polymers (pGlc₁₀₀, pGal₁₀₀, pFuc₁₀₀, Glc₁₀₀, Gal₁₀₀ and Fuc₁₀₀) were prepared with matching spectra as literature.²

pGal₅Fuc₅ ¹H NMR (700 MHz, CDCl₃) δ 7.36 (m), 5.91 (br, s), 5.42 (br, s), 5.35 (br, s), 5.30 (br, s), 5.19 (br, s), 5.16 (br, s), 5.05 (br, s), 4.52 (br, s), 4.16 (br, s), 3.98 (br, s), 3.87 (br, s), 3.77 (m), 3.54 (br, s), 3.35 (br, s), 3.06 (br, s), 2.72 (br, s), 2.47 (br, s), 2.32 (br, s), 2.30 (br, s), 2.19 (br, s), 2.18 (br, s), 2.09 (br, s), 2.07 (br, s), 2.02 (br, s), 1.88 (m), 1.67 (br, s), 1.16 (br, s).

pGal₁₅Fuc₁₅ ¹H NMR (700 MHz, CDCl₃) δ 7.36 (m), 5.94 (br, s), 5.42 (br, s), 5.35 (br, s), 5.30 (br, s), 5.19 (br, s), 5.16 (br, s), 5.05 (br, s), 4.54 (br, s), 4.16 (br, s), 3.99 (br, s), 3.87 (br, s), 3.77 (m), 3.54 (br, s), 3.35 (br, s), 3.07 (br, s), 2.73 (br, s), 2.47 (br, s), 2.32 (br, s), 2.30 (br, s), 2.19 (br, s), 2.18 (br, s), 2.09 (br, s), 2.07 (br, s), 2.02 (br, s), 1.88 (m), 1.67 (br, s), 1.16 (br, s).

pGal₅₀Fuc₅₀ ¹H NMR (700 MHz, CD₂Cl₂) δ 7.38 (br, s), 7.31 (br, s), 7.27 (br, s), 5.94 (br, s), 5.42 (br, s), 5.34 (br, s), 5.29 (br, s), 5.23 (br, s), 5.13 (br, s), 5.06 (br, s), 4.56 (br, s), 4.17 (br, s), 4.01 (br, s), 3.86 (br, s), 3.74 (m), 3.70 (br, s), 3.58 (br, s), 3.37 (br, s), 3.06 (br, s), 2.72 (br, s), 2.30 (br, s), 2.18 (s), 2.08 (br, s), 2.06 (s), 2.00 (br, s), 1.88 (m), 1.68 (br, s), 1.15 (br, s). ¹³C NMR (125 MHz, CDCl₃) δ 174.51 170.54 170.29 170.12 169.95 169.51 101.31 96.44 71.04 70.88 68.94 68.10 67.94 67.21 65.64 64.59 61.45 42.17 38.97 36.98 20.72 20.52 20.47 20.44 20.39 15.74 15.09.

Gal₅Fuc₅ ¹H NMR (700 MHz, D₂O) δ 7.35 (br, s), 7.31 (br, s), 7.22 (br, s), 5.31 (br, s), 5.25 (br, s), 5.17 (br, s), 4.76 (br, s), 4.27 (br, s), 3.88 (br, s), 3.83 (s), 3.72 (br, s), 3.67 (s), 3.58 (br, s), 3.54 (br, s), 3.44 (br, s), 3.39 (br, s), 3.31 (br, s), 3.24 (br, s), 2.93 (br, s), 2.83 (br, s), 2.64 (br, s), 2.51 (br, s), 2.40 (br, s), 1.90 (br, s), 1.73 (br, s), 1.56 (br, s), 1.11 (s).

Gal₁₅Fuc₁₅ ¹H NMR (700 MHz, D₂O) δ 7.33 (br, s), 7.30 (br, s), 7.22 (br, s), 5.32 (br, s), 5.25 (br, s), 5.16 (br, s), 4.77 (br, s), 4.27 (br, s), 3.88 (br, s), 3.83 (s), 3.72 (br, s), 3.67 (s), 3.58 (br, s), 3.54 (br, s), 3.44 (br, s), 3.39 (br, s), 3.31 (br, s), 3.24 (br, s), 2.93 (br, s), 2.84 (br, s), 2.64 (br, s), 2.51 (br, s), 2.40 (br, s), 1.90 (br, s), 1.73 (br, s), 1.56 (br, s), 1.11 (s).

Gal₅₀Fuc₅₀ ¹H NMR (700 MHz, D₂O) δ 7.30 (br, s), 7.21 (br, s), 5.31 (br, s), 5.24 (br, s), 5.15 (br, s), 4.77 (br, s), 4.27 (br, s), 3.88 (br, s), 3.83 (s), 3.74 (br, s), 3.67 (s), 3.55 (br, s), 3.54 (br, s), 3.45 (br, s), 3.40 (br, s), 3.31 (br, s), 3.24 (br, s), 2.93 (br, s), 2.84 (br, s), 2.64 (br, s), 2.51 (br, s), 2.40 (br, s), 1.92 (br, s), 1.75 (br, s), 1.57 (br, s), 1.11 (s). ¹³C NMR (176 MHz, D₂O) δ 177.77 103.11 98.40 75.08 72.72 71.78 70.74 69.59 68.47 68.01 66.57 60.88 51.80 51.56 48.80 43.61 41.75 39.13 36.46 15.65.




Figure S1. GPC traces of polymers displaying 100 sugar units.




Figure S2. GPC traces of polymers with varying degrees of polymerization.




Figure S3. Gating strategy for murine MLN cells.

Only live and single cells were included for further analysis of CTB binding.




Figure S4. Gating strategy for murine small intestinal cells.

Only live and single EpCAM+ cells were included for further analysis of CTB binding.




Figure S5. Flow cytometry evaluation of glycol-polymers to block CTB binding to murine lymphocytes.

Cells were isolated from murine MLN, stained with cell markers and stained with CTB-bio to analyze polymer block in flow cytometry. Full gating can be seen in Figure S3. Panel (A) and (C) show representative histograms of CTB binding to B and T cells with or without polymer block. Panel (B) and (D) show graphs of geometric mean fluorescence index (gMFI) for CTB binding after polymer block. The values are normalized to % of unblocked CTB gMFI. Curve fits were made using a three-parameter fit to equation 1. Data pooled from 3 independent experiments with 2-3 mice in each experiment where error bars represent SD.




Figure S6. Gating strategy for human small intestinal cells.

Only live and single EpCAM+ cells were included for further analysis of CTB binding.





Figure S7. Gating strategy for human enteroid cells.

Only live and single EpCAM+ cells were included for further analysis of CTB binding.

Current Data Parameters
NAME 20170922_p127_F2_41-60
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20170922
Time 16.21 h
INSTRUM spect
PROBHD Z122624_0008 (
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 10000.000 Hz
FIDRES 0.152588 Hz
AQ 3.2767999 sec
RG 55.72
DW 50.000 usec
DE 10.00 usec
TE 298.1 K
D1 1.00000000 sec
TDO 1
SFO1 499.8930868 MHz
NUC1 1H
P1 12.00 usec
PLW1 15.69999981 W

F2 - Processing parameters
SI 65536
SF 499.8900000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



¹H-NMR spectrum of monomer 1a'



```

Current Data Parameters
NAME      20180205_p180_13
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     20180205
Time      13.11 h
INSTRUM   spect
PROBHD    z123952_0005 (
PULPROG   zg30
TD        65536
SOLVENT   CDCl3
NS        16
DS        2
SWH       14097.744 Hz
FIDRES    0.430229 Hz
AQ        2.3243434 sec
RG        11.08
DW        35.467 usec
DE        16.00 usec
TE        298.1 K
D1        1.00000000 sec
TD0       1
SFO1      700.1343233 MHz
NUC1      1H
P1        8.00 usec
PLW1      9.60000038 W

F2 - Processing parameters
SI        65536
SF        700.1300178 MHz
WDW       EM
SSB       0
LB        0.30 Hz
GB        0
PC        1.00

```




¹H-NMR spectrum of monomer **1b'**


Current Data Parameters
NAME 20190219_p311_15
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190219
Time 15.57 h
INSTRUM spect
PROBHD z123952_0005 (
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 14097.744 Hz
FIDRES 0.430229 Hz
AQ 2.3243434 sec
RG 11.08
DW 35.467 usec
DE 16.00 usec
TE 298.2 K
D1 1.00000000 sec
TD0 1
SFO1 700.1343233 MHz
NUC1 1H
P1 8.00 usec
PLW1 9.60000038 W


F2 - Processing parameters
SI 65536
SF 700.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




¹H-NMR spectrum of monomer 1c'




¹H-NMR spectrum of pGlc₁₀₀




¹H-NMR spectrum of pGal₁₀₀




¹H-NMR spectrum of pFuc₁₀₀




¹H-NMR spectrum of pGal₅₀Fuc₅₀




Stacked ¹H-NMR spectra of pGal₅Fuc₅ (green), pGal₁₅Fuc₁₅ (red) and pGal₅₀Fuc₅₀ (blue) in CDCl₃




¹H-NMR spectrum of Glc₁₀₀



¹H-NMR spectrum of Gal₁₀₀



¹H-NMR spectrum of FuC₁₀₀



Current Data Parameters
 NAME 20180313_p194_13_p192_G50F50
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters

Date_ 20180313
 Time 17.52 h
 INSTRUM spect
 PROBHD Z123952_0005 (
 PULPROG zg30
 TD 65536
 SOLVENT D2O
 NS 16
 DS 2
 SWH 14097.744 Hz
 FIDRES 0.430229 Hz
 AQ 2.3243434 sec
 RG 14.11
 DW 35.467 usec
 DE 16.00 usec
 TE 298.2 K
 D1 1.00000000 sec
 TD0 1
 SFO1 700.1343233 MHz
 NUC1 1H
 P1 8.00 usec
 PLW1 9.60000038 W

F2 - Processing parameters

SI 65536
 SF 700.1300000 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

¹H-NMR spectrum of Gal₅₀FuC₅₀



Stacked $^1\text{H-NMR}$ spectra of Gal_5Fuc_5 (green), $\text{Gal}_{15}\text{Fuc}_{15}$ (red) and $\text{Gal}_{50}\text{Fuc}_{50}$ (blue) in D_2O

References

1. Pulsipher, A.; Yousaf, M. N., A renewable, chemoselective, and quantitative ligand density microarray for the study of biospecific interactions. *Chem Commun (Camb)* **2011**, 47 (1), 523-5.
2. Wu, L.; Sampson, N. S., Fucose, mannose, and beta-N-acetylglucosamine glycopolymers initiate the mouse sperm acrosome reaction through convergent signaling pathways. *ACS Chem Biol* **2014**, 9 (2), 468-75.
3. Patil, B. S.; Babu, V. V. S., A rapid and convenient synthesis of α and β forms of acetylated derivatives of sugars under microwave irradiation. *Indian Journal of Chemistry* **2004**, 43B, 1288-1291.
4. Hauck, D.; Joachim, I.; Frommeyer, B.; Varrot, A.; Philipp, B.; Moller, H. M.; Imberty, A.; Exner, T. E.; Titz, A., Discovery of two classes of potent glycomimetic inhibitors of *Pseudomonas aeruginosa* LecB with distinct binding modes. *ACS Chem Biol* **2013**, 8 (8), 1775-84.
5. Bucher, K. S.; Konietzny, P. B.; Snyder, N. L.; Hartmann, L., Heteromultivalent Glycooligomers as Mimetics of Blood Group Antigens. *Chemistry* **2019**, 25 (13), 3301-3309.
6. Ni, J.; Singh, S.; Wang, L. X., Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins. *Bioconjug Chem* **2003**, 14 (1), 232-8.